"For these reasons, we believe that the name 'Pacific Biomarkers, Inc.' more accurately reflects both our current and historical strengths. The term 'biomarker' is now much more widely known and is broadly understood to have a key role in drug development. Therefore, the new name accurately positions us as a specialty laboratory provider for contemporary drug development services," concluded Helm.
Also at the Annual Meeting, stockholders re-elected the seven members of the Company's Board of Directors:
Ronald R. Helm Mario R. Ehlers Paul G. Kanan Richard W. Palfreyman Curtis J. Scheel Stanley L. Schloz Kenneth R. Waters
The third proposal on the agenda at the Annual Meeting, which was also approved by the stockholders, ratified the Audit Committee's selection of PMB Helin Donovan, LLP as the Company's independent auditors for the 2010 fiscal year. PMB Helin Donovan, LLP has audited the Company's financial statements since September 5, 2007.
About Pacific Biometrics, Inc. (PBI)
Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laborator
|SOURCE Pacific Biometrics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved